Showing 2891-2900 of 5771 results for "".
- Hoya Vision Care Expands MiYOSMART Power Range for High Myopia Treatment in Childrenhttps://modernod.com/news/hoya-vision-care-expands-miyosmart-power-range-for-high-myopia-treatment-in-children/2482630/Hoya Vision Care announced the launch of an extended power range for its MiYOSMART spectacle lenses, offering a new solution for children suffering from high myopia. Designed specifically to address the needs of high myopic patients, the new lenses feature a broader range of prescriptions, slimme
- MERIT Acquires OSOD to Expand Ophthalmic Drug Development Serviceshttps://modernod.com/news/merit-acquires-osod-to-expand-ophthalmic-drug-development-services/2482629/MERIT announced its has acquired OSOD, which assists with ophthalmic preclinical drug development. The acquisition enhances MERIT’s capabilities, enabling a transition from preclinical to clinical phases of drug development. Accordin
- Pantheon Vision Advances Corneal Implant Developmenthttps://modernod.com/news/pantheon-vision-advances-corneal-implant-development/2482627/Pantheon Vision announced the completion of its third meeting with the FDA review team as the company continues its development of bioengineered corneal implants, designed to address the global challenge of corneal blindness. Over the past year, Pan
- RayOne EMV Toric IOL Approved by Health Canadahttps://modernod.com/news/rayone-emv-toric-iol-approved-by-health-canada/2482626/Rayner announced the approval of RayOne EMV Toric IOL by Health Canada. Developed in collaboration with Professor Graham Barrett, RayOne EMV and RayOne EMV Toric are the only patented aspheric IOLs that induce controlled positive spherical aberration to extend depth of focus, according
- Nacuity Pharmaceuticals Granted FDA Fast Track Designation for NPI-001 Tablets for RPhttps://modernod.com/news/nacuity-pharmaceuticals-granted-fda-fast-track-designation-for-npi-001-tablets-for-retinitis-pigmentosa/2482625/Nacuity Pharmaceuticals announced that the FDA has granted Fast Track Designation to NPI-001 (N-acetylcysteine amide) tablets, Nacuity’s proprietary investigational therapy for the treatment of patients with retinitis pigmentosa (RP). A drug may receive Fast Track designation
- Formycon Receives EU Approval for Eylea Biosimilar FYB203 Under the Brand Names Ahzantive and Baiamahttps://modernod.com/news/formycon-receives-eu-approval-for-eylea-biosimilar-fyb203-under-the-brand-names-ahzantive-and-baiama/2482624/Formycon and its licensing partner Klinge Biopharma jointly announce that the European Commission has granted central marketing authorization for FYB203 (aflibercept), a biosimilar to Eylea, under the brand names Ahzantive and Baiama. The app
- HelpMeSee Expands Simulation-based Cataract Surgery Training with New Partnerships at USC and UIChttps://modernod.com/news/helpmesee-expands-simulation-based-cataract-surgery-training-with-new-partnerships-at-usc-and-uic/2482623/HelpMeSee has announce its latest training partnerships with the University of Southern (USC)/LA General Medical Center in Los Angeles, and the University of Illinois Chicago (UIC). These collaborations establish two new
- Prevent Blindness Receives Legacy Donation of $9.7 Million, Largest in Historyhttps://modernod.com/news/prevent-blindness-receives-legacy-donation-97-million-largest-in-history/2482622/Prevent Blindness announced it has received a donation of $9.7 million from the Estate of Pamela Behrens, a Florida resident and previous donor. Founded in 1908, this is the largest donation the organization has ever received. Ms. Behrens made the donation in honor of her late hus
- PulseSight Therapeutics Initiates Clinical Plan of PST-611 Transferrin Vectorized Therapy for Dry AMD/GAhttps://modernod.com/news/pulsesight-therapeutics-initiates-clinical-plan-of-pst-611-transferrin-vectorized-therapy-for-dry-amdga/2482615/PulseSight Therapeutics SAS announced it has submitted a clinical trial authorization (CTA) to Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) for a phase 1 trial (PST-611-CT1) assessing the safety
- Bausch + Lomb Makes Two Deals to Bolster Therapeutic Pipeline in GA and Glaucomahttps://modernod.com/news/bausch-lomb-makes-two-deals-to-bolster-therapeutic-pipeline-in-ga-and-glaucoma/2482612/Bausch + Lomb announced two separate deals to acquire early- and mid-stage therapeutic assets. First, B+L, through an affiliate, acquired Whitecap Biosciences LLC, which is developing two therapies for potential use in glaucoma and geographic atrophy (GA). Financial terms